Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $11.8 Million - $14.8 Million
319,027 Added 2727.43%
330,724 $12.5 Million
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $427,408 - $569,176
11,697 New
11,697 $517,000
Q4 2020

Feb 16, 2021

SELL
$45.3 - $60.27 $5.96 Million - $7.93 Million
-131,618 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$47.45 - $62.95 $6.25 Million - $8.29 Million
131,618 New
131,618 $6.25 Million
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $525,891 - $685,286
-11,225 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$41.6 - $63.4 $229,132 - $349,207
5,508 Added 96.34%
11,225 $531,000
Q4 2019

Feb 13, 2020

BUY
$53.85 - $65.27 $307,860 - $373,148
5,717 New
5,717 $345,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.64B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.